This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Human mammary gland cells under the microscope, pink overlay
    Congress highlights
    16/10/25

    ESMO Breast Cancer 2022 – Congress Highlights

    Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/04/22

    CHMP recommends change of approval of Keytruda in triple negative breast cancer.- MSD

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

    Guidelines
    Guideline
    01/10/23

    ESMO expert consensus statements on the management of breast cancer during pregnancy (PrBC)

    The European Society for Medical Oncology (ESMO) has issued expert consensus statements on managing breast cancer during pregnancy (PrBC), a rare and complex clinical scenario. These recommendations, developed through a multidisciplinary process, aim to balance maternal treatment needs with fetal safety in the absence of randomized trial data.

    • Source: European Society for Medical Oncology (ESMO)
    Human mammary gland cells under the microscope, pink overlay
    Congress highlights
    13/10/25

    Expert wrap up interview – Professor Nadia Harbeck

    Join Professor Nadia Harbeck, Director of the Breast Centre at LMU University Hospital in Munich, Germany, as she shares her insights on the key developments for breast cancer treatment that emerged at ESMO Breast Cancer 2022.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    19/12/22

    CHMP recommends Enhertu to treat HER2-low breast cancer

    The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Enhertu. The marketing authorisation holder for this medicinal product is Daiichi Sankyo Europe GmbH and licensee is AstraZeneca

    African american mid adult female nurse using smart phone while holding clipboard in hospital
    Insight
    26/06/18

    Medical cannabis - a novel approach to pain control

    In the last 30 years or so there has been increased attention on the medical uses of cannabis and its constituent chemicals. Cannabis itself contains at least 60 active cannabinoids, one of which, cannabidiol (CBD)...

     
    Guidelines
    Guideline
    01/08/23

    ESMO expert consensus statements on on the definition, diagnosis, and management of HER2-low breast cancer

    The European Society for Medical Oncology (ESMO) has released expert consensus statements on HER2-low breast cancer, a newly recognized and targetable subtype. These statements address biology, diagnosis, treatment, and clinical trial design, aiming to guide oncologists in managing HER2-low metastatic disease.

    • Source: European Society for Medical Oncology (ESMO)
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/04/22

    NICE recommends tucatinib + trastuzumab + capecitabine to treat HER-2 positive breast cancer.- Seagen

    National Institute for Health and Care Excellence (NICE) recommends;Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies Technology appraisal guidance [TA786]Published: 27 April 2022.

    Human mammary gland cells under the microscope, pink overlay
    Congress highlights
    13/10/25

    ESMO Breast Cancer 2022 – Day 2

    Follow all the latest developments with daily highlights from the European Society of Medical Oncology Breast Cancer Congress in Berlin, Germany, 3–5 May 2022.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    28/08/24

    Phase III clinical study of fezolinetant is initiated for VMS in women with breast cancer receiving adjuvant endocrine therapy

    Astellas Pharma Inc. announced dosing of the first patient in the HIGHLIGHT 1 Phase III pivotal study for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) in women with breast cancer receiving adjuvant endocrine therapy

    See more